Package Leaflet: Information for the User
Supemtek Tetra injectable solution
Influenza vaccine (tetralent, recombinant, prepared in cell culture)
This medicinal product is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will tell you how to report side effects.
Read all of this leaflet carefully before you are vaccinated because it contains important information for you.
Contents of the package leaflet
Supemtek Tetra is a vaccine for adults and children from 9 years of age. This vaccine helps protect you against influenza virus. Supemtek Tetra does not contain egg due to the technology used to produce it.
How Supemtek Tetra works
When a person receives Supemtek Tetra, the body's natural defenses (the immune system) produce protection against the influenza virus. None of the vaccine components can cause influenza.
As with all vaccines, Supemtek Tetra may not fully protect all people who are vaccinated.
When to administer the influenza vaccine
Influenza can spread very quickly.
Your doctor will recommend the best time for you to get vaccinated.
Do not use Supemtek Tetraif you are allergic to:
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before starting to use Supemtek Tetra.
As with all vaccines, Supemtek Tetra may not fully protect all people who are vaccinated.
Before receiving the vaccine, tell your doctor, nurse, or pharmacist if:
If any of the above applies to you (or you are not sure), tell your doctor, pharmacist, or nurse before receiving Supemtek Tetra.
Other medicines and Supemtek Tetra
Tell your doctor or nurse if you are using, have recently used, or might use any other medicines, including medicines obtained without a prescription or if you have recently received any other vaccine.
Supemtek Tetra can be administered at the same time as other vaccines using separate limbs.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or plan to become pregnant, ask your doctor or pharmacist for advice before using this vaccine. Your doctor/pharmacist will help you decide if you should receive Supemtek Tetra.
Driving and using machines
Supemtek Tetra has no or negligible influence on the ability to drive and use machines.
Supemtek Tetra contains sodium
This medicine contains less than 23 mg of sodium (1mmol) per dose unit, which is essentially "sodium-free".
Your doctor, nurse, or pharmacist will administer Supemtek Tetra as an injection into the upper arm (deltoid muscle).
Adults and children from 9 years of age:
A dose of 0.5 ml.
Like all medicines, this vaccine can cause side effects, although not everybody gets them.
Severe allergic reactions
Immediatelycontact your doctor or healthcare professional or go immediately to the emergency department of the nearest hospital if you have an allergic reaction, as it can be life-threatening.
Symptoms include:
The following adverse reactions have been reported with Supemtek Tetra:
Other side effects
Very common (may affect more than 1 in 10 people):
Muscle pain and joint pain are common in adults 50 years of age and older.
Common (may affect up to 1 in 10 people):
Fever is rare in adults 50 years of age and older.
Bruising is reported in children/adolescents 9 to 17 years of age.
Uncommon (may affect up to 1 in 100 people):
Itching is rare in adults 50 years of age and older.
Neither skin irritation nor skin rash has been reported in adults 50 years of age and older.
Flu-like symptoms have not been reported in adults 18 to 49 years of age.
Vomiting, decreased appetite, abdominal discomfort, and asthma have not been reported in adults 18 years of age and older.
Rare (may affect up to 1 in 1,000 people):
Neither dizziness nor hives has been reported in adults 18 to 49 years of age.
Dizziness is uncommon in children/adolescents 9 to 17 years of age.
Frequency not known (cannot be estimated from the available data):
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V*. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store in a refrigerator (between 2°C and 8°C). Do not freeze.
Store the pre-filled syringe in the outer packaging to protect it from light.
Do not use this vaccine after the expiry date which is stated on the label and carton after EXP.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Supemtek Tetra
One dose (0.5 ml) contains:
The active substances are hemagglutinin proteins (HA) of the influenza virus of the following strains*:
Strain similar to A/XXXXXX (H1N1) 45 micrograms HA
Strain similar to A/XXXXXX (H3N2) 45 micrograms HA
Strain similar to B/XXXXXX 45 micrograms HA
Strain similar to B/XXXXXX 45 micrograms HA
This vaccine complies with the recommendation of the World Health Organization (Northern Hemisphere) and with the recommendation of the European Union for the XXXX/XXXX season.
The other ingredients are: polysorbate 20 (E432), sodium chloride, sodium phosphate monobasic, sodium phosphate dibasic, water for injections (see section 2).
Appearance and packaging of the product
Supemtek Tetra is an injectable solution in a pre-filled syringe (ready-to-use syringe).
Supemtek Tetra is a clear and colorless solution, essentially free from visible particles.
A single syringe contains 0.5 ml of injectable solution.
Supemtek Tetra is available in packs containing 1, 5, or 10 pre-filled syringes without a needle or with a separate needle.
Not all pack sizes may be marketed.
Marketing authorization holder
Sanofi Winthrop Industrie, 82 Avenue Raspail, 94250 Gentilly, France
Manufacturer
Sanofi Winthrop Industrie
Voie de l’Institut - Parc Industriel d'Incarville
B P 101
27100 Val de Reuil
France
You can ask for more information about this medicine from the local representative of the marketing authorization holder:
België/Belgique/Belgien Sanofi Belgium Tél/Tel.: +32 02 710.54.00 | Lietuva Swixx Biopharma UAB Tel: +370 5 236 91 40 |
Swixx Biopharma EOOD Тел.: +359 (0) 2 4942 480 | Luxembourg/Luxemburg Sanofi Belgium tel.: +32 2 710.54.00 |
Ceská republika Sanofi s.r.o. Tel: +420 233 086 111 | Magyarország sanofi-aventis zrt Tel.: +36 1 505 0055 |
Danmark Sanofi A/S Tel: +45 4516 7000 | Malta Sanofi S.r.l. Tel: +39 02 39394275 |
Deutschland Sanofi-Aventis Deutschland GmbH Tel.: 0800 54 54 010 Tel. from abroad: +49 69 305 21 130 | Nederland Sanofi B.V. Tel: +31 20 245 4000 |
Eesti Swixx Biopharma OÜ Tel: +372 640 10 30 | Norge Sanofi-aventis Norge AS Tel: + 47 67 10 71 00 |
Ελλάδα ΒΙΑΝΕΞ Α.Ε. Τηλ: +30.210.8009111 | Österreich Sanofi-Aventis GmbH Tel: +43 (1) 80185-0. |
España sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Polska Sanofi sp. z o.o. Tel.: +48 22 280 00 00 |
France Sanofi Winthrop Industrie Tél: 0800 222 555 Appel depuis l’étranger : +33 1 57 63 23 23 | Portugal Sanofi – Produtos Farmacêuticos, Lda. Tel: + 351 21 35 89 400 |
Hrvatska Swixx Biopharma d.o.o. Tel: +385 1 2078 500 | România Sanofi Romania SRL Tel.: +40(21) 317 31 36 |
Ireland sanofi-aventis Ireland T/A SANOFI Tel: + 353 (0) 1 4035 600 | Slovenija Swixx Biopharma d.o.o. Tel: +386 1 235 51 00 |
Ísland Vistor Tel : +354 535 7000 | Slovenská republika Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 |
Italia Sanofi S.r.l. Tel: 800536389 | Suomi/Finland Sanofi Oy Tel: +358 (0) 201 200 300 |
Κύπρος C.A. Papaellinas Ltd. Τηλ: +357 22 741741 | Sverige Sanofi AB Tel: +46 8-634 50 00 |
Latvija Swixx Biopharma SIA Tel: +371 6 616 47 50 | United Kingdom(Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525 |
Date of last revision of this leaflet:MM/AAAA
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
--------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Medical treatment and appropriate supervision should be available in case of an anaphylactic episode following administration of the vaccine.
The vaccine should be inspected visually for particles and discoloration before administration. If any foreign particles and/or variation in physical appearance are observed, do not administer the vaccine.